NCT04266938 (RAPID) is a NA clinical trial of Rapid start of antiretrovirals in HIV-1-infection, sponsored by University of Louisville.

Who is sponsoring NCT04266938?

NCT04266938 is sponsored by University of Louisville.

What drugs are being tested in NCT04266938?

Interventions in NCT04266938: Rapid start of antiretrovirals, Retrospective analysis, Non- RAPID start.

What condition does NCT04266938 study?

NCT04266938 studies HIV-1-infection.

Is NCT04266938 still recruiting?

NCT04266938 is currently completed. Last updated 6 August 2025.

Last reviewed 2025-08-06 · How we verify

NCT04266938: RAPID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Rapid ART Initiation on Retention in Care in the Southern US

Completed NA Last updated 6 August 2025

What this trial tests

NA trial testing Rapid start of antiretrovirals in HIV-1-infection in 258 participants. Completed in 30 May 2024.

Timeline

1 June 2021

Primary endpoint
31 March 2024

30 May 2024

Quick facts

Lead sponsor	University of Louisville
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	other
Enrollment	258
Start date	1 June 2021
Primary completion	31 March 2024
Estimated completion	30 May 2024
Sites	1 location across United States

Drugs / interventions tested

Rapid start of antiretrovirals
Retrospective analysis
Non- RAPID start

Conditions studied

HIV-1-infection — all drugs for HIV-1-infection →

Sponsor

University of Louisville

Who can join

18 and older, any sex, with HIV-1-infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Impact of Rapid ART Initiation on Retention in Care in the Southern US Specific Goals and Aims: The major goal for this study is to determine if rapid start of antiretroviral (ART) therapy increases retention in HIV medical care. The investigators hypothesize that there will be an increase in retention in care with rapid start, by removing barriers that would normally delay enrollment in a treatment program and enforce the importance of linkage to care and ART initiation from diagnosis. In order to test this hypothesis, the investigators have the following specific aims for their proposed study: 1. Study retention in care after rapid ART start in comparison to standard of care. 2. Analyze risk factors for decreased retention in care, with focus on high-risk populations. 3. Analyze potential demographic and geographic determinants of retention in care. 4. Generate retention in care data in a Southern US state. The investigators hypothesize the introduction of rapid start ART, as well as the introduction of care navigators, will lead to improved clinical outcomes, including retention in care at one year, viral suppression at one year, time to viral suppression, and time to first missed appointment. In the event rapid start ART fails to have a positive impact on clinical outcomes, the results of this study will still positively contribute to the knowledge gap, since there is a scarcity of data in the Southern United States, specifically in high-risk populations, such as racial and ethnic minorities, youth, and patients co-infected with hepatitis C.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for HIV-1-infection

Currently open trials in the same condition.

NCT07293559 — Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States · recruiting
NCT06919016 — A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1- · Phase 1 · active not recruiting
NCT06554717 — Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV · Phase 2 · recruiting
NCT06774872 — Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Succes · Phase 2 · recruiting
NCT06890988 — Ending the Epidemic Interventions in the Dental Setting - UH3 · NA · recruiting

Other University of Louisville trials

Trials by the same sponsor.

NCT07219888 — Comparison of Suzetrigine and Oxycodone for Postoperative Pain After Primary Total Knee Arthroplasty · Phase 4 · not yet recruiting
NCT07044726 — Betadine vs Sterile Water for Periurethral Preparation · Phase 4 · not yet recruiting
NCT06489106 — Noninvasive Spinal Stimulation to Restore Hand Function in Children With Spinal Cord Injury · NA · enrolling by invitation
NCT06883513 — Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID · NA · recruiting
NCT05920720 — Self-Guided Personalized Treatment for Women · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04266938 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Louisville
Last refreshed: 6 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04266938.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing